Regeneron reports sustained Pasatru efficacy through week 84
Regeneron said Pasatru maintained efficacy and a consistent safety profile from weeks 56 to 84, with tolerability sustained through week 84.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
According to the Newsmetry API, Regeneron Pharmaceuticals said Pasatru demonstrated sustained efficacy from week 56 through week 84.
The company also reported a consistent safety profile for the treatment. Regeneron Pharmaceuticals said Pasatru maintained a well-tolerated safety profile through week 84.
why it matters
The update provides information on Pasatru’s durability and tolerability, factors relevant to how investors and pharmaceutical-market participants assess the treatment.
instruments
sources
- Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84 — Newsmetry API, 12 October 2026 at 16:32 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗